'That's Huge, Folks': Amarin's Vascepa Cuts CV Risk By 25% On Top Of Statins

 
• By Mandy Jackson

Cardiovascular outcomes data exceeded expectations for the fish oil pill, vindicating Amarin, which has fought long and hard for Vascepa's place in the CV disease prevention market. A filing based on REDUCE-IT is expected in early 2019.

Dart arrow hitting in the target center of dartboard using as background Target business, achieve and victory,success concept.

More from Clinical Trials

More from R&D